Ensartinib as a neoadjuvant therapy for stage IIIA non-small cell lung cancer patients with EML4-ALK fusion: a case report and literature review

Anaplastic lymphoma kinase (ALK) inhibitors have shown efficacy in treating ALK-positive advanced non-small cell lung cancer (NSCLC) patients. However, the effectiveness of ensartinib neoadjuvant therapy remains ambiguous. Herein, we reported that preoperative systemic treatment with the ALK inhibit...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Hao Zhang, Wei Xia, Yifan Zhang, Shihao Bao, Jingtong Zeng, Xianjie Li, Bo Zhang, Hanqing Wang, Song Xu, Zuoqing Song
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Subjects:	ensartinib EML4-ALK fusion neoadjuvant non-small cell lung cancer immune microenvironment
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1474997/full